There are undoubtedly individuals and very small g
Post# of 148110
In support of my contention I looked at approvals of novel drugs in 2021. there were 50 drugs approved. Of those 50 drugs, 15 seemed to come from small biopharmas that did not have a development deal in place prior to approval. My look for partnerships was not exhaustive so I may be wrong on a few.
Argenx - Vyvgart
Mirum Pharmaceuticals - Livmarli
Ascendis Pharma - Skytrofa
Albireo Pharma - Bylvay
Kadmon Corporation - Rezurock
SCYNEXIS - Brexafemme
QED Therapeutics/BridgeBio Pharma - Truseltiq
Lantheus Holdings - Pylarify
ADC Therapeutics - Zynlonta
Mayne Pharma Group/Mithra Pharmaceuticals - Nextstellis
Supernus Pharmaceuticals - Qelbree
AVEO Oncology/EUSA Pharma - Fotivda
Origin Biosciences/BridgeBio Pharma - Nulibry
G1 Therapeutics - Cosela
Aurinia Pharmaceuticals -Lupkynis